# Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019

> **NCT04371601** · EARLY_PHASE1 · UNKNOWN · sponsor: **Fuzhou General Hospital** · enrollment: 60 (actual)

## Conditions studied

- COVID-19 Pneumonia

## Interventions

- **DRUG:** Oseltamivir
- **DRUG:** hormones
- **DEVICE:** oxygen therapy
- **PROCEDURE:** mesenchymal stem cells

## Key facts

- **NCT ID:** NCT04371601
- **Lead sponsor:** Fuzhou General Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-03-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04371601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04371601, "Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04371601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*